Mesothelioma.com Resources for Patients and their Families

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Brief Summary

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-181. This study will also evaluate the safety and tolerability of ABBV-181 in combination with Rovalpituzumab Tesirine. The study will consist of 2 parts: ABBV-181 monotherapy dose escalation and expansion, and ABBV-181 in combination with Rovalpituzumab Tesirine.

Tracking Information
First Received DateDecember 15, 2016
Last Changed DateNovember 15, 2017
Start DateDecember 20, 2016
Anticipated Primary Completion DateJune 12, 2018
Primary Outcome Measures

Number of participants with adverse events [Time Frame: From first dose of study drug until 90 days following last dose of study drug (up to 24 months)]

Recommended Phase 2 Dose (RPTD) for ABBV-181 [Time Frame: Up to 6 months]

Maximum tolerated dose (MTD) of ABBV-181 [Time Frame: Up to 6 months]

Maximum observed serum concentration (Cmax) [Time Frame: Up to 12 weeks after participant's first dose]

Time to Cmax (Tmax) [Time Frame: Up to 12 weeks after participant's first dose]

Area under the serum concentration time curve (AUC) [Time Frame: Up to 12 weeks after participant's first dose]

Terminal half-life (t1/2) [Time Frame: Up to 4 weeks after participant's first dose]

Recommended Phase 2 Dose (RPTD) and schedule for ABBV-181 and Rovalpituzumab Tesirine combination [Time Frame: Up to 6 months]

Secondary Outcome Measures

Objective response rate (ORR) [Time Frame: First dose of study drug through at least 30 days after end of treatment; up to 24-month treatment period]

Clinical benefit rate (CBR, defined as CR, PR or SD) [Time Frame: First dose of study drug through at least 30 days after end of treatment; up to 24-month treatment period]

Progression-free survival (PFS) [Time Frame: First dose of study drug through at least 30 days after end of treatment; up to 24-month treatment period]

Duration of objective response (DOR) [Time Frame: First dose of study drug through at least 30 days after end of treatment; up to 24-month treatment period]

Preliminary response and activity of ABBV-181 and Rovalpituzumab Tesirine when given in combination [Time Frame: First dose of study drug through at least 30 days after end of treatment; up to 24-month treatment period]

Descriptive Information
PhasePhase 1
Study TypeInterventional
Condition
  • Advanced Solid Tumors
Intervention
  • Drug: ABBV-181
  • Drug: Rovalpituzumab Tesirine
Study Arms / Comparison Groups2 / 0
Recruitment Information
Recruitment StatusRecruiting
Anticipated Enrollment182
GenderAll
Ages18 Years - 99 Years
Accepts Healthy VolunteersNo
Contact AbbVie_Call Center
Email: abbvieclinicaltrials@abbvie.com
Phone: 847.283.8955
Eligibility Criteria

Inclusion Criteria:

- Participant must have an advanced solid tumor and must not be a candidate for surgical resection or other approved therapeutic regimen known to provide clinical benefit. For dose escalation, the participant may have been previously treated with a programmed cell death 1 (PD-I) targeting agent. For dose expansion, the participant must be PD-I/PD-L1 targeting agent naïve. For Combination, the participant must be have SCLC with progressive disease and have failed platinum containing therapy and be PD-1/PD-L1 targeting agent naïve.

- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2 for Monotherapy and 0 to 1 for Combination.

- Participants have adequate bone marrow, renal, hepatic and coagulation function.

- Participants must have measurable or evaluable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 in the dose escalation portion of the trial. Participants in the expansion cohort must have measurable disease per RECIST version 1.1 or disease evaluable by assessment of tumor antigens.

Exclusion Criteria:

- Participant has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives, prior to the first dose of ABBV-181 or Rovalpituzumab Tesirine.

- For Combination therapy, participant must not have had prior exposure to Rovalpituzumab Tesirine or a pyrrolobenzodiazepine (PBD) based drug.

- Participant has unresolved adverse events greater than grade 1 from prior anticancer therapy except for alopecia.

- Current or prior use of immunosuppressive medication within 14 days prior to the first dose (with certain exceptions).

- History of primary immunodeficiency, bone marrow transplantation, chronic lymphocytic leukemia, solid organ transplantation, or previous clinical diagnosis of tuberculosis.

- Confirmed positive test results for human immunodeficiency virus (HIV), or participants with chronic or active hepatitis B or C. Subjects who have a history of hepatitis B or C who have undetectable HBV DNA or HCV RNA are anti-viral therapy may be enrolled.

- Participant has known history or inflammatory bowel disease, pneumonitis, or known uncontrolled metastases to the central nervous system (CNS) (with certain exceptions).

Administrative Information
NCTIDNCT03000257
Responsible Party,
SponsorAbbVie
Verification DateNovember 2017
Mesothelioma Doctors by State
  • Breaking News
  • Emerging Clinical Trials
  • Delivered within 24 hrs

Yes   No

Mesothelioma Cancer Alliance Blog

FEATURED CONTENT:


RECENT POSTS:

How Brazil’s Asbestos Ban Impacts the Rest of the World

Jenni DeHart Remembers Her Father’s Battle with Stage 4 Pleural Mesothelioma

Talcum Powder Lawsuits: How Asbestos-Contaminated Talc Harms People

Mesothelioma Treatment Guide

Free Mesothelioma Treatment Guide

Please fill in the form below to request our FREE Mesothelioma Treatment Guide. It will be sent to you within 24 hours.

Have you or someone you know been diagnosed with mesothelioma?

Get Access To: